P. P. Tak

7.7k total citations · 1 hit paper
38 papers, 2.0k citations indexed

About

P. P. Tak is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, P. P. Tak has authored 38 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 13 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in P. P. Tak's work include Rheumatoid Arthritis Research and Therapies (16 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Systemic Lupus Erythematosus Research (7 papers). P. P. Tak is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Systemic Lupus Erythematosus Research (7 papers). P. P. Tak collaborates with scholars based in Netherlands, United States and United Kingdom. P. P. Tak's co-authors include Carla A. Wijbrandts, Ben A. C. Dijkmans, Willem F. Lems, Michael T. Nurmohamed, LA Aarden, Gertjan Wolbink, Steven O. Stapel, G. M. Bartelds, Margriet J. Vervoordeldonk and Rogier M. Thurlings and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Biochemical Society Transactions.

In The Last Decade

P. P. Tak

35 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

2007 448 citations G. M. Bartelds, Carla A. Wijbrandts et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by P. P. Tak

Since Specialization

Citations

This map shows the geographic impact of P. P. Tak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. P. Tak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. P. Tak more than expected).

Fields of papers citing papers by P. P. Tak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. P. Tak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. P. Tak. The network helps show where P. P. Tak may publish in the future.

Co-authorship network of co-authors of P. P. Tak

This figure shows the co-authorship network connecting the top 25 collaborators of P. P. Tak. A scholar is included among the top collaborators of P. P. Tak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. P. Tak. P. P. Tak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single vagus nerve stimulation reduces early postprandial C-peptide levels but not other hormones or postprandial metabolism 2017 ·Clinical Rheumatology ·Man Tang, F. Samuel van Nierop, Frieda A. Koopman, Hannah M. Eggink, Daniëlle M. Gerlag, (unknown), Ralph Zitnik, Frédéric M. Vaz, Johannes A. Romijn, P. P. Tak, Maarten R. Soeters	6
2	Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis 2014 ·Annals of the Rheumatic Diseases ·(unknown), E. Suzanne Cohen, Daniëlle M. Gerlag, Jamie I. D. Campbell, John Woods, Neil Davis, Annemarie van Nieuwenhuijze, Arthur Lewis, (unknown), Matthew McCourt, D Corkill, (unknown), Julia A. Elvin, (unknown), Ian P. Wicks, Ian K. Anderson, Andrew D. Nash, (unknown), P. P. Tak	60
3	First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial 2012 ·Data Archiving and Networked Services (DANS) ·Frank Behrens, Mikkel Østergaard, Румен Стоилов, Piotr Wiland, T. Huizinga, (unknown), P. P. Tak, (unknown), Jürgen Rech, Andrea Rubbert‐Roth, Mariusz Korkosz, (unknown), И. А. Зупанец, B Ejbjerg, Jens Geiseler, (unknown), Roman Korolkiewicz, Arndt Schottelius, Harald Burkhardt	9
4	Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease 2012 ·Annals of the Rheumatic Diseases ·P. L. Klarenbeek, Maria J. H. de Hair, Marieke E. Doorenspleet, Barbera D. C. van Schaik, R. E. Esveldt, M. G. H. Van de Sande, Tineke Cantaert, Daniëlle M. Gerlag, Dominique Baeten, Antoine H. C. van Kampen, Frank Baas, P. P. Tak, Niek de Vries	104
5	Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue 2012 ·Gene Therapy ·Federico Mingozzi, (unknown), (unknown), (unknown), Rogier M. Thurlings, P. P. Tak, Katherine A. High, Margriet J. Vervoordeldonk	113
6	The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study 2011 ·Lara D. Veeken ·Ruth Klaasen, Tineke Cantaert, Carla A. Wijbrandts, Christine A. Teitsma, D M Gerlag, T.A. Out, (unknown), (unknown), P. P. Tak	51
7	The BLIMP-1 risk allele is associated with increased synovial inflammation in rheumatoid arthritis 2011 ·Annals of the Rheumatic Diseases ·Marieke M. J. Herenius, Lisa G. M. van Baarsen, Paul L. Klarenbeek, Carla A. Wijbrandts, Juan D. Cañete, Robert M. Plenge, P. P. Tak, Niek de Vries	2
8	Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial 2011 ·Arthritis & Rheumatism ·Mark C. Genovese, Nils Kinnman, Guillaume de La Bourdonnaye, Claudia Peña Rossi, P. P. Tak	98
9	Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) 2010 ·Lara D. Veeken ·Andrea Rubbert‐Roth, P. P. Tak, Cristiano A. F. Zerbini, (unknown), Luis Carreño, G. Armstrong, Neil Collinson, T. Shaw, (unknown)	139
10	Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor α7 subunit gene knockout mice 2010 ·Annals of the Rheumatic Diseases ·Marjolein A. van Maanen, Susanne P. Stoof, G J LaRosa, Margriet J. Vervoordeldonk, P. P. Tak	107
11	Work ability: a new outcome measure in rheumatoid arthritis? 2010 ·Scandinavian Journal of Rheumatology ·Hennie G. Raterman, Jan L. Hoving, Michael T. Nurmohamed, Marieke M. J. Herenius, J. K. Sluiter, Willem F. Lems, P. P. Tak, Ben A. C. Dijkmans, Jos W. R. Twisk, Monique H. W. Frings‐Dresen, Alexandre E. Voskuyl	23
12	Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients 2007 ·Annals of the Rheumatic Diseases ·Tineke C. T. M. van der Pouw Kraan, Carla A. Wijbrandts, Lisa G. M. van Baarsen, Alexandre E. Voskuyl, François Rustenburg, Josefien M. Baggen, Saleh Ibrahim, Mike Fero, Ben A. C. Dijkmans, P. P. Tak, C L Verweij	234
13	Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating, single‐ and repeated‐dose study 2007 ·Arthritis & Rheumatism ·P. P. Tak, Rogier M. Thurlings, (unknown), Ivan Nestorov, (unknown), (unknown), Maureen Rischmueller, Е. Л. Насонов, Е. Шмидт, Paul Emery, Alain Munafo	171
14	Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis breakdown → 2007 ·Annals of the Rheumatic Diseases ·G. M. Bartelds, Carla A. Wijbrandts, Michael T. Nurmohamed, Steven O. Stapel, Willem F. Lems, LA Aarden, Ben A. C. Dijkmans, P. P. Tak, Gertjan Wolbink	448
15	[TNF-blocking drugs and infection; recommendations for daily practice]. 2007 ·PubMed ·Johannes W. G. Jacobs, M.C.W. Creemers, Michiel A. van Agtmael, M.A.F.J. van de Laar, Tom van der Poll, P. P. Tak, J. W. J. Bijlsma	2
16	CTLA‐4IG suppresses reactive oxygen species by preventing synovial adherent cell–induced inactivation of rap1, a ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells 2006 ·Arthritis & Rheumatism ·(unknown), C A Wijbrandts, M. Sanders, René E. M. Toes, FC Breedveld, P. P. Tak, Jacob M. van Laar, Kris A. Reedquist	38
17	Intracellular free radical production in synovial T lymphocytes from patients with rheumatoid arthritis 2005 ·Arthritis & Rheumatism ·(unknown), M. van Oosterhout, Tom Smeets, M. Sanders, Wilma M. Frederiks, Kris A. Reedquist, P. P. Tak, FC Breedveld, Jacob M. van Laar	63
18	Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis 2001 ·Annals of the Rheumatic Diseases ·Maarten C. Kraan, Malcolm Smith, Helen Weedon, Michael Ahern, FC Breedveld, P. P. Tak	52
19	Detection of mycobacteria in joint samples from patients with arthritis using a genus-specific polymerase chain reaction and sequence analysis 1999 ·Lara D. Veeken ·Ineke M. van der Heijden, Bert Wilbrink, Leo M. Schouls, J D van Embden, FC Breedveld, P. P. Tak	39
20	NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. 1999 ·PubMed ·Karlfried R. Aupperle, Brydon L. Bennett, David L. Boyle, P. P. Tak, Anthony M. Manning, Gary S. Firestein	90

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact